TrialThe New England journal of medicine2017
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
Scott J Antonia et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
2,589 papers cite itlatest 60 shown
this paperpooled ittrialcites it